数据见证，从内容到品牌的转化 转自：健民集团 龙牡壮骨颗粒独家冠名播出的《乐在旅途》历时三年，三季共与33座城市结缘，在这些城市地标的位置举办了34场户外演唱会，共计收获热搜567个，全网总共获得过60亿+频次浏览量。 全网话题热搜近300个。其中，微博主榜热搜22个，主话题#央视乐在旅途#、#乐在旅途#总阅读量11亿；抖音热搜119个；主话题#乐在旅途#央视乐在旅途 及相关话题衍生话题总浏览量17.1 在第 32 届中国国际广告节中，健民集团龙牡壮骨颗粒与《乐在旅途》第三季 "共壮成长" 的深度合作案例，成功摘得 "2025年度整合营销金案" 大奖！ 情感共鸣，实现品牌价值升华 《乐在旅途》与龙牡壮骨颗粒的三季同行，节目以30城音乐山河图为画卷，将品牌深度融入非遗传承、文化自信的时代叙事中，使龙牡壮骨颗粒从健康产品升华为文化守护的参与者。 龙牡壮骨颗粒的这趟"寻音"旅途证明，当传统品牌学会用故事、新语言、新情感讲述，让品牌在年轻观众心中扎根发芽。 这份"2025年度整合营销金案"大奖，不仅是对过去成绩的肯定，更是对未来方向的引领。 品牌植入升级，从"看见"到"记住" 在第三季节目中，龙牡壮骨颗粒通过具象化I ...

Core Viewpoint - Jianmin Group (600976) has received the Clinical Trial Approval Notice for Yimufuyin Granules from the National Medical Products Administration [1] Group 1 - Jianmin Group announced the receipt of the approval notice on the evening of October 27 [1]

证券简称：健民集团 证券代码：600976 公告编号：2025-036 健民药业集团股份有限公司 关于获得《药物临床试验批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局签发的益母妇炎颗粒《药物临床试验批准通知书》。按照《上海证券交易所 上市公司自律监管指引第3号——行业信息披露》的相关要求，现将有关情况公告 如下： 益母妇炎颗粒为公司自主研发的中药1.1类创新药，截至本公告披露日，该产 品尚未在国内外上市。 一、药品的基本情况 | 药品名称 | 益母妇炎颗粒 | 申请人 | 健民药业集团股份有限公司 | | --- | --- | --- | --- | | 注册分类 | 中药1.1类 | 剂型 | 颗粒剂 | | 通知书编号 | 2025LP02794 | 受理号 | CXZL2500058 | | 适应症 | 盆腔炎性疾病后遗症慢性盆腔痛 | | | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，202 ...

Core Points - The Ministry of Industry and Information Technology announced the seventh batch of national industrial heritage sites and the third batch of sites that passed re-evaluation, including 32 new sites and 50 re-evaluated sites [1][2]. Group 1: New National Industrial Heritage Sites - The seventh batch includes significant projects such as Shoushan Substation, Fengman Hydropower Station, Jingpo Lake Power Plant, Qinshan Nuclear Power Station, and Chongqing Power Plant [1][2]. Group 2: Re-evaluated National Industrial Heritage Sites - The third batch of re-evaluated sites includes major locations like Dagang Oilfield Port No. 5 Well, Kailuan Zhao Gezhuang Mine, Shigejie Coal Mine, Fushun West Open-pit Mine, Dongwo Hydropower Station, and the Controlled Nuclear Fusion Experiment Site [1][2]. Group 3: Recommendations for Heritage Management - The Ministry encourages local departments and enterprises to enhance the systematic protection of industrial heritage, increase resource support, and promote active utilization through new models such as "Industrial Heritage +” for education, tourism, and industrial restructuring [2].

Core Viewpoint - Jianmin Group reported a decline in both revenue and net profit for the first three quarters of 2025, indicating challenges in its business operations [1] Financial Performance - For the first three quarters of 2025, the company's operating revenue was 2.55 billion yuan, a year-on-year decrease of 11.4% [1] - The net profit attributable to shareholders was 286 million yuan, down 11.16% year-on-year [1] - The net profit excluding non-recurring items was 256 million yuan, reflecting a decline of 5.58% year-on-year [1] Quarterly Breakdown - In the third quarter, the operating revenue was 747 million yuan, showing a year-on-year decrease of 14.3% [1] - The net profit attributable to shareholders for the third quarter was 65.11 million yuan, down 20.8% year-on-year [1] - The net profit excluding non-recurring items for the third quarter was 60.22 million yuan, a decline of 21.3% year-on-year [1] Segment Analysis - From the beginning of the year to the reporting period, the company's operating revenue decreased by 11.43%, with the pharmaceutical manufacturing segment experiencing a growth of 19.67% due to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue by 36.91%, attributed to the company's ongoing optimization of its commercial subsidiaries' business structure and the gradual reduction of low-margin and inefficient operations [1]

Core Viewpoint - The financial performance of Jianmin Group (600976) for the third quarter of 2025 shows a decline in revenue and net profit compared to the previous year, primarily due to a significant drop in pharmaceutical commercial income, despite growth in pharmaceutical manufacturing revenue. Financial Performance Summary - **Revenue**: The total revenue for the third quarter was approximately 747.33 million yuan, representing a year-on-year decrease of 14.27%. For the year-to-date, revenue was approximately 2.55 billion yuan, down 11.43% from the previous year [3][4]. - **Net Profit**: The net profit attributable to shareholders was approximately 65.11 million yuan for the quarter, down 20.84% year-on-year. Year-to-date net profit was approximately 285.74 million yuan, a decrease of 11.16% [3][5]. - **Cash Flow**: The net cash flow from operating activities for the year-to-date increased by 31.45%, amounting to approximately 139.05 million yuan, attributed to increased industrial sales collections [3][4]. Segment Performance - **Pharmaceutical Manufacturing**: Revenue from pharmaceutical manufacturing increased by 19.67% year-on-year, driven by growth in leading and new products [5]. - **Pharmaceutical Commerce**: Revenue from pharmaceutical commerce decreased by 36.91%, primarily due to a strategic shift to optimize business structure and reduce low-margin operations [5]. Shareholder Information - The largest shareholder is Huali Pharmaceutical Group Co., Ltd., holding 24.15% of the shares. Other significant shareholders include Hong Kong Central Clearing Limited and Huali Group Co., Ltd. [7]. Market Activity - On October 22, 2025, Jianmin Group's stock closed at 39.77 yuan, down 1.78%, with a turnover rate of 1.29% and a trading volume of 19,800 shares, resulting in a transaction value of approximately 78.86 million yuan [1][2]. - The net outflow of main funds on the same day was approximately 13.08 million yuan, accounting for 16.59% of the total transaction value [2][4].

Core Viewpoint - The company reported a decline in revenue and net profit for the year-to-date period, primarily due to changes in its business structure and reduced investment income [3][4]. Financial Performance - Year-to-date revenue decreased by 11.43%, with the pharmaceutical manufacturing segment growing by 19.67% due to increased sales of main and new products, while the pharmaceutical commercial segment saw a decline of 36.91% due to the optimization of business structure [3]. - The net profit attributable to shareholders decreased by 11.16%, mainly due to reduced investment income from associates and non-recurring gains [3]. Non-Recurring Gains and Losses - The report indicates that there are no significant non-recurring gains or losses that have been classified incorrectly [4]. Shareholder Information - There are no changes in the top ten shareholders or any significant movements in share lending activities [6]. Audit Status - The financial statements for the third quarter are unaudited, and the company has not applied new accounting standards for the current reporting period [8].

Core Insights - The company reported a revenue of 2.552 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 11.43% [1] - The net profit attributable to shareholders was 286 million yuan, down 11.16% year-on-year [1] Revenue Breakdown - The pharmaceutical manufacturing segment experienced a revenue increase of 19.67% year-on-year, driven by growth in the company's leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant revenue decline of 36.91%, attributed to the company's ongoing optimization of its commercial subsidiaries and the gradual reduction of low-margin and inefficient businesses [1] Profit Analysis - The decrease in net profit was primarily due to reduced investment income from joint ventures and a decline in non-recurring gains and losses [1]

Core Viewpoint - Jianmin Group reported a decline in both revenue and net profit for the third quarter of 2025, indicating ongoing financial challenges for the company [1] Financial Performance - In Q3 2025, the company achieved a revenue of 747 million yuan, a year-on-year decrease of 14.27% [1] - The net profit attributable to shareholders for the same period was 65.11 million yuan, down 20.84% year-on-year [1] - For the first three quarters of 2025, the total revenue reached 2.552 billion yuan, reflecting an 11.43% decline compared to the previous year [1] - The net profit attributable to shareholders for the first three quarters was 286 million yuan, which is an 11.16% decrease year-on-year [1]

Core Insights - The core viewpoint of the article highlights the financial performance of Jianmin Group for the third quarter of 2025, indicating a decline in both revenue and net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company's operating revenue was 747 million yuan, a year-on-year decrease of 14.27% [1] - The net profit for Q3 2025 was 65.11 million yuan, down 20.84% year-on-year [1] - For the first three quarters of 2025, the total operating revenue reached 2.552 billion yuan, reflecting an 11.43% decline compared to the same period last year [1] - The net profit for the first three quarters was 286 million yuan, which is an 11.16% decrease year-on-year [1] - The basic earnings per share stood at 1.88 yuan [1] Segment Performance - The pharmaceutical manufacturing segment experienced a year-on-year growth of 19.67%, attributed to increased revenue from leading and new products [1] - Conversely, the pharmaceutical commercial segment saw a significant decline in revenue, down 36.91%, due to the company's ongoing optimization of its commercial subsidiaries' business structure, leading to a reduction in low-margin and inefficient operations [1]